RXRX — Recursion Pharmaceuticals, Inc. - Class A Common Stock
Session close: $3.46. Regular-session share volume: 38,493,699. Change from previous close: -16.71%.
Key developments
Sanofi selected the first development candidate from its Recursion collaboration, triggering a milestone payment and taking responsibility for funding and leading further development. This advances the partnership, although additional milestones and royalties remain contingent.
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know · Sanofi (ENXTPA:SAN) Adds AI Immunology Candidate As Fair Value Questions Persist
Recursion also priced a share offering; completion was not confirmed. Posters on X highlighted dilution concerns and cautioned that the offering price need not provide a floor. These concerns offer context for the decline, but causation is not established; the news trading commentary covered the prior session and after-hours activity.
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know · Source post by @HayabusaRes · Source post by @LSbyMO
Separately, posters on X viewed expanded clinical data as encouraging and said financing lengthened the cash runway, while flagging unresolved registrational endpoints and further validation needs. These are limited, unverified opinions, not established explanations for the session’s move.
Source post by @Biobeats99 · Source post by @HayabusaRes
News sources
Company news Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know · Company news Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar